布地奈德福莫特罗联合噻托溴铵治疗COPD的效果分析

Effect analysis of budesonide formoterol combined with tiotropium bromide in the treatment of COPD

目的观察布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的临床效果。方法 80例COPD患者,采用随机数字抽取法分为对照组和观察组,每组40例。对照组患者采用布地奈德福莫特罗粉吸入剂治疗,观察组患者在对照组基础上增加噻托溴铵治疗,比较两组患者治疗效果。结果治疗前,两组患者最大肺活量(VCmax)、第1秒用力呼气容积(FEV1)、最高呼气流量(PEF)、FEV1/占用力肺活量百分比(FEV1/FVC)水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者VCmax、FEV1、PEF、FEV1/FVC水平分别为(2.68±0.44)L、(2.02±0.23)L、(4.89±0.66)L/s、(74.96±6.59)%,均优于对照组的(2.15±0.48)L、(1.64±0.36)L、(3.56±0.34)L/s、(68.31±7.57)%,差异具有统计学意义(P<0.05)。结论布地奈德福莫特罗联合噻托溴铵能够明显改善COPD患者的肺功能,值得临床推广应用。

Objective To observe the clinical effect of budesonide formoterol combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease(COPD). Methods A total of 80 COPD patients were divided by random number table method into control group and observation group, with 40 cases in each group. The control group was treated with budesonide formoterol powder inhaler, and the observation group was treated with tiotropium bromide on the basis of the control group. The treatment effect in two groups was compared. Results Before treatment, both groups had no statistically significant difference in maximum vital capacity(VCmax), forced expiratory volume in 1 second(FEV1), peak expiratory flow(PEF) and FEV1/forced vital capacity(FEV1/FVC)(P>0.05). After treatment, the observation group had better VCmax, FEV1, PEF and FEV1/FVC level respectively as(2.68±0.44) L,(2.02±0.23) L,(4.89±0.66) L/s and(74.96±6.59)% than(2.15± 0.48) L,(1.64±0.36) L,(3.56±0.34) L/s and(68.31±7.57)% in the control group, and their difference was statistically significant(P<0.05). Conclusion Combination of budesonide formoterol and tiotropium bromide can obviously improve the lung function of COPD patients, and it is worthy of clinical promotion and application.